Piperidine and pyrrolidine analogs as glycogen synthase activators; a patent evaluation (WO2011058122).
A small series of piperidine analogs that effectively activate glycogen synthase (GS) was prepared in WO2011058122. The treatment or prophylaxis of metabolic disease and disorders by these novel GS activators is claimed. These compounds represent further variations around a structural motif explored in the prior patent publications by Roche.
Daiichi Sankyo Co., Ltd, Lead Discovery & Optimization Research Laboratories I, 1-2-58, Hiromachi, Shinagawa-ku, Tokyo, 140-8710, Japan. uto.yoshikazu.pw@daiichisankyo.co.jp
Yoshikazu
Y
Uto
D000818:Animals; D015195:Drug Design; D006006:Glycogen Synthase / Q000187:drug effects* / Q000378:metabolism; D006801:Humans; D008659:Metabolic Diseases / Q000188:drug therapy / Q000201:enzymology / Q000503:physiopathology; D010330:Patents as Topic; D010880:Piperidines / Q000737:chemistry / Q000494:pharmacology*; D011759:Pyrrolidines / Q000737:chemistry / Q000494:pharmacology*
D010880:Piperidines; D011759:Pyrrolidines; D006006:Glycogen Synthase